Ceregate's software complements existing therapies for neurological disorders such as Parkinson's disease. The startup, founded in 2019, is also developing new therapeutic approaches in the field of neurostimulation. For example, the Munich-based company has developed a method to incorporate the process of so-called "mindwriting" into today's conventional deep brain stimulation and other neuromodulation systems. Deep brain stimulation involves implanting hardware into the patient's brain or spinal cord that uses electrical impulses to treat certain disorders such as Parkinson's disease, epilepsy, or pain. By combining the two approaches, Ceregate's CBI technology can "write" or "transmit" information into the brain instead of simply passively interpreting ongoing neural activity.
After Ceregate secured funding from the High-Tech Gründerfonds (HTGF) After receiving funding and successfully completing a proof-of-concept study with over 15 patients, the startup has now raised more capital. HTGF is again participating in the Series A financing round. However, the lead investor is the European health tech investor Heal Capital. Truventuro has also joined the round. The new financing—the amount of which was not disclosed—will enable Ceregate to further develop its approaches and conduct clinical trials to commercialize the first products.
"Today, we are able to transmit information directly into the brain—this is a revolutionary step. With our platform, we have all the prerequisites to understand and fundamentally rethink the role of supporting information in neurological therapy. We look forward to beginning this next chapter on our journey together with our new partners,"
explained Balint Varkuti, Founder and CEO of Ceregate.
Ceregate convinces investors
The investors are convinced of the startup’s potential. Eckhardt Weber, General Partner at Heal Capital, explains:
"The application of cutting-edge software to existing brain stimulation devices is a fantastic technology that can dramatically improve patients' quality of life. With Ceregate, a leading healthtech company in the field of computer-brain interaction has emerged from Germany, which fits perfectly into our investment area. It demonstrates how the interplay of science, technology, and medicine can have a tremendous impact on how we can improve the treatment of complex diseases in the future."
And Tobias Faupel, Senior Investment Manager at HTGF, adds:
"The excellent clinical data demonstrates CereGate's remarkable progress since our seed investment last year. We are impressed by the speed and execution strength of the Ceregate team and were therefore pleased to participate in this financing round."
